Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IAPP | P10997 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9837137 | 0.85 | CA1 (0.44) | MAPTLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL9837143 | 0.85 | CA1 (0.44) | MAPTLMNAKDM4ESMN1; SMN2HTT | |
| SCHEMBL12569680 | 0.81 | CYP1A2 (0.34) | LMNAKDM4ESMN1; SMN2CYP1A2RAB9A | |
| SCHEMBL13017801 | 0.78 | TRPV1 (0.52) | MAPTLMNAKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL19339161 | 0.73 | APLNR (0.50) | LMNAKDM4ESMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL4317195 | 0.72 | PARP1 (0.41) | LMNAKDM4ECYP1A2HTTTDP1 | |
| SCHEMBL21767548 | 0.70 | LMNA (0.44) | MAPTLMNAKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL21767547 | 0.70 | LMNA (0.44) | MAPTLMNAKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL29955945 | 0.70 | CYP1A2 (0.41) | MAPTLMNAKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL1599165 | 0.70 | CYP1A2 (0.41) | MAPTLMNAKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354359-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | MAPT 3318/4885LMNA 2012/4885KDM4E 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.